Interchange Capital Partners LLC Sells 6,042 Shares of Tempus AI, Inc. $TEM

Key Points

• Interchange Capital Partners LLC significantly reduced its holdings in Tempus AI by 90.3% during Q2, selling 6,042 shares and ending up with only 650 shares valued at $41,000.
• Tempus AI's quarterly revenue surged by 89.5% year-over-year, amounting to $314.64 million, despite reporting a loss of ($0.22) EPS, which slightly beat analyst expectations.
• Insider trading has been notable, with both the COO and CEO selling significant shares, contributing to a decrease in their ownership of the company's stock by 2.04% and 3.51%, respectively.

Interchange Capital Partners LLC lowered its holdings in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 90.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 650 shares of the company's stock after selling 6,042 shares during the period. Interchange Capital Partners LLC's holdings in Tempus AI were worth $41,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Concord Wealth Partners raised its position in shares of Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company's stock valued at $26,000 after buying an additional 308 shares in the last quarter. Cherry Tree Wealth Management LLC acquired a new position in shares of Tempus AI in the 1st quarter valued at approximately $31,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Tempus AI in the 1st quarter valued at approximately $33,000. Bartlett & CO. Wealth Management LLC raised its position in shares of Tempus AI by 100.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company's stock valued at $39,000 after buying an additional 400 shares in the last quarter. Finally, Nemes Rush Group LLC acquired a new position in shares of Tempus AI in the 1st quarter valued at approximately $39,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Trading Up 2.3%

NASDAQ:TEM opened at $91.91 on Thursday. The firm's fifty day moving average is $81.00 and its 200-day moving average is $65.55. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32. The firm has a market cap of $15.97 billion, a P/E ratio of -77.24 and a beta of 4.87.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The company had revenue of $314.64 million for the quarter, compared to analyst estimates of $296.84 million. During the same period in the prior year, the firm posted ($6.86) EPS. The company's quarterly revenue was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. Equities analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Insider Buying and Selling at Tempus AI

In related news, COO Ryan Fukushima sold 17,460 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $1,303,389.00. Following the transaction, the chief operating officer directly owned 839,180 shares of the company's stock, valued at $62,644,787. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 332,500 shares of the stock in a transaction on Thursday, September 25th. The stock was sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the transaction, the chief executive officer directly owned 9,141,032 shares in the company, valued at approximately $699,837,409.92. This represents a 3.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 933,662 shares of company stock valued at $68,070,993 over the last 90 days. Insiders own 26.27% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on TEM. Needham & Company LLC reiterated a "buy" rating and set a $70.00 price objective on shares of Tempus AI in a research report on Friday, August 8th. Guggenheim upped their price target on shares of Tempus AI from $80.00 to $95.00 and gave the company a "buy" rating in a research report on Friday, September 26th. HC Wainwright upped their price target on shares of Tempus AI from $90.00 to $98.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Piper Sandler restated a "neutral" rating on shares of Tempus AI in a research report on Friday, August 8th. Finally, Morgan Stanley upped their price target on shares of Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a research report on Tuesday, August 12th. Seven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $71.83.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.